Dong-A ST returns to the KRW 160 billion mark after two years
Samsung Biologics, the first in the pharmaceuticalㆍbio industry to exceed KRW 650 billion
[Newsmp] The atmosphere of the listed pharmaceutical companies, whose closing accounts are in December, is hot as they have begun to announce their second-quarter earnings.
On the 20th, Hanmi Pharmaceutical was the first to announce its tentatively counted second quarter result, and on the 27th, six pharmaceutical companies joined the actual disclosure.
Among them, five pharmaceutical companies reported double-digit sales growth, heating up the early vibe.
In particular, Boryung Pharmaceutical surpassed KRW 170 billion with 21.4% sales growth in the second quarter, and Ildong Pharmaceutical also exceeded KRW 160 billion with 14.6% growth.
Hanmi Pharmaceutical posted sales of KRW 316.5 billion at a 13.3% growth rate, reporting sales of the KRW 300 billion mark again following the second quarter of last year.
Moreover, Korea United Pharmaceutical’s sales exceeded KRW 60 billion with a growth rate of 13.2%, and HanAll Biopharma also achieved a double-digit growth rate of 12.0%.
Dong-A ST’s sales growth rate was 8.7%, which did not reach double digits, but it surpassed KRW 160 billion again in two years since the first quarter of 2020.
However, Bukwang Pharmaceutical was the only company to record negative growth (-2.7%) among the seven pharmaceutical companies that announced preliminary earnings by the 27th.
Most of the listed pharmaceutical companies that announced their preliminary earnings by the 27th had double-digit sales growth, but operating profit was mixed by company.
Boryung Pharmaceutical’s operating profit, which recorded sales growth of over 20% in the second quarter, also surged 64.4%, and Hanmi Pharmaceutical’s operating profit soared 86.4% to close to KRW 30 billion. Korea United Pharm’s operating profit also surged 32.1%, exceeding KRW 10 billion.
On the other hand, HanAll Biopharma’s operating profit plunged 69.1%, Dong-A ST 45.1%, Ildong Pharmaceutical’s losses nearly tripled, and Bukwang Pharmaceutical’s deficit continued.
In the meantime, Samsung Biologics achieved KRW 651.4 billion in sales in the second quarter, surpassing KRW 650 billion in quarterly sales for the first time in the pharmaceutical/bio industry.
